FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4298007366> ?p ?o ?g. }

• W4298007366 endingPage "1296" @default.
• W4298007366 startingPage "1282" @default.
• W4298007366 abstract "The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) and the cholesterol-lowering medication ezetimibe are widely used in the treatment of patients with high- and very high-risk atherosclerotic cardiovascular disease. This study compared the efficacy and tolerability of a fixed-dose combination (FDC) of ezetimibe/atorvastatin (EZ/AS) with those of escalating doses of atorvastatin monotherapy in Chinese patients with hypercholesterolemia uncontrolled with statin monotherapy.This Phase III, 12-week, randomized, double-blind study included patients aged 18 to 80 years with hypercholesterolemia uncontrolled on atorvastatin 10 or 20 mg/d monotherapy. After a 5-week run-in period of treatment with atorvastatin 10 or 20 mg/d (cohorts A and B, respectively), or a bioequivalent dosage of another statin, patients were randomized in a 1:1 ratio within each cohort to receive EZ/AS 10/10 mg FDC (EZ10/AS10) or atorvastatin 20 mg (AS20), once daily (cohort A); or EZ/AS 10/20 mg FDC (EZ10/AS20) or atorvastatin 40 mg (AS40), once daily (cohort B). The primary end point was the percentage change from baseline in low-density lipoprotein cholesterol (LDL-C). Tolerability was also evaluated.Of the 454 patients enrolled, 412 (90.7%) completed the study. The percentage change from baseline in LDL-C was statistically greater with EZ10/AS10 treatment (n = 88) compared with AS20 monotherapy (n = 89) (treatment difference, -19.5%; 95% CI, -26.7% to -12.3%; P < 0.001). The percentage change from baseline in LDL-C was statistically greater with EZ10/AS20 treatment (n = 137) compared with AS40 monotherapy (n = 140) (treatment difference, -15.9%; 95% CI, -21.0% to -10.7%; P < 0.001). The safety profile was comparable between the EZ/AS and atorvastatin groups in the two cohorts.The LDL-C level at week 12 was significantly improved with both FDCs compared with escalated doses of atorvastatin (20 or 40 mg/d) in these Chinese patients with hypercholesterolemia uncontrolled on atorvastatin 10 or 20 mg/d. Both FDCs were well tolerated, with no new tolerability-related findings. Chinadrugtrials.org.cn identifier: CTR20190172; ClinicalTrials.gov identifier: NCT03768427." @default.
• W4298007366 created "2022-10-01" @default.
• W4298007366 creator A5000393913 @default.
• W4298007366 creator A5001737088 @default.
• W4298007366 creator A5021293751 @default.
• W4298007366 creator A5034764782 @default.
• W4298007366 creator A5055657571 @default.
• W4298007366 creator A5056941518 @default.
• W4298007366 creator A5068556809 @default.
• W4298007366 creator A5078164215 @default.
• W4298007366 creator A5088869525 @default.
• W4298007366 creator A5089746504 @default.
• W4298007366 date "2022-10-01" @default.
• W4298007366 modified "2023-09-26" @default.
• W4298007366 title "Efficacy and Tolerability of Ezetimibe/Atorvastatin Fixed-dose Combination Versus Atorvastatin Monotherapy in Hypercholesterolemia: A Phase III, Randomized, Active-controlled Study in Chinese Patients" @default.
• W4298007366 cites W1031089084 @default.
• W4298007366 cites W1945607940 @default.
• W4298007366 cites W1977399475 @default.
• W4298007366 cites W1984688884 @default.
• W4298007366 cites W1999164183 @default.
• W4298007366 cites W2000071979 @default.
• W4298007366 cites W2025041596 @default.
• W4298007366 cites W2031485860 @default.
• W4298007366 cites W2071155446 @default.
• W4298007366 cites W2078849257 @default.
• W4298007366 cites W2082559134 @default.
• W4298007366 cites W2111099202 @default.
• W4298007366 cites W2155417522 @default.
• W4298007366 cites W2163455636 @default.
• W4298007366 cites W2200285648 @default.
• W4298007366 cites W2333896373 @default.
• W4298007366 cites W2496801530 @default.
• W4298007366 cites W2554418576 @default.
• W4298007366 cites W2584408389 @default.
• W4298007366 cites W2636265553 @default.
• W4298007366 cites W2735904008 @default.
• W4298007366 cites W2737874043 @default.
• W4298007366 cites W2791568876 @default.
• W4298007366 cites W2801513610 @default.
• W4298007366 cites W2897098703 @default.
• W4298007366 cites W2900848740 @default.
• W4298007366 cites W2909765747 @default.
• W4298007366 cites W2919192762 @default.
• W4298007366 cites W2920274846 @default.
• W4298007366 cites W2946627926 @default.
• W4298007366 cites W2985198456 @default.
• W4298007366 cites W3001476701 @default.
• W4298007366 cites W3006057482 @default.
• W4298007366 cites W3087468833 @default.
• W4298007366 cites W3091022330 @default.
• W4298007366 cites W3153390842 @default.
• W4298007366 cites W3155692460 @default.
• W4298007366 cites W3162784462 @default.
• W4298007366 cites W3195996039 @default.
• W4298007366 cites W3196862885 @default.
• W4298007366 cites W3200580168 @default.
• W4298007366 cites W3203110973 @default.
• W4298007366 cites W4229334849 @default.
• W4298007366 cites W4236673002 @default.
• W4298007366 doi "https://doi.org/10.1016/j.clinthera.2022.08.013" @default.
• W4298007366 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36182594" @default.
• W4298007366 hasPublicationYear "2022" @default.
• W4298007366 type Work @default.
• W4298007366 citedByCount "4" @default.
• W4298007366 countsByYear W42980073662022 @default.
• W4298007366 countsByYear W42980073662023 @default.
• W4298007366 crossrefType "journal-article" @default.
• W4298007366 hasAuthorship W4298007366A5000393913 @default.
• W4298007366 hasAuthorship W4298007366A5001737088 @default.
• W4298007366 hasAuthorship W4298007366A5021293751 @default.
• W4298007366 hasAuthorship W4298007366A5034764782 @default.
• W4298007366 hasAuthorship W4298007366A5055657571 @default.
• W4298007366 hasAuthorship W4298007366A5056941518 @default.
• W4298007366 hasAuthorship W4298007366A5068556809 @default.
• W4298007366 hasAuthorship W4298007366A5078164215 @default.
• W4298007366 hasAuthorship W4298007366A5088869525 @default.
• W4298007366 hasAuthorship W4298007366A5089746504 @default.
• W4298007366 hasBestOaLocation W42980073661 @default.
• W4298007366 hasConcept C126322002 @default.
• W4298007366 hasConcept C168563851 @default.
• W4298007366 hasConcept C197934379 @default.
• W4298007366 hasConcept C2776623344 @default.
• W4298007366 hasConcept C2776839432 @default.
• W4298007366 hasConcept C2777482532 @default.
• W4298007366 hasConcept C2778375690 @default.
• W4298007366 hasConcept C2778657065 @default.
• W4298007366 hasConcept C71924100 @default.
• W4298007366 hasConcept C72563966 @default.
• W4298007366 hasConcept C90924648 @default.
• W4298007366 hasConcept C98274493 @default.
• W4298007366 hasConceptScore W4298007366C126322002 @default.
• W4298007366 hasConceptScore W4298007366C168563851 @default.
• W4298007366 hasConceptScore W4298007366C197934379 @default.
• W4298007366 hasConceptScore W4298007366C2776623344 @default.
• W4298007366 hasConceptScore W4298007366C2776839432 @default.
• W4298007366 hasConceptScore W4298007366C2777482532 @default.
• W4298007366 hasConceptScore W4298007366C2778375690 @default.
• W4298007366 hasConceptScore W4298007366C2778657065 @default.

• next